Clinical effect and safety evaluation of Danhong injection in the treatment after cardiac interventional therapy / 中国生化药物杂志

ABSTRACT

Objective To investigate the efficacy and cardiovascular disease of Danhong injection in the treatment after cardiac interventional therapy.Methods A total of 64 cases with cardiac intervention from September 2013 to July 2015 in our hospital were selected and divided into control group and experiment group with 32 cases in each group.Patients in the control group were given aspirin 100mg orally,and patients in the experiment group revieved Danhong injection 20mL intravenous drip qd,one times a day for 14 days.Two groups of patients underwent cardiac intervention.After the operaiton,the control group was given aspirin enteric-coated tablets 100mg orally,clopidogrel 75mg orally,and patients in the experiment group revieved Danhong injection 20mL intravenous drip qd,seven days for a course and the patients treated for three courses.The clinical efficacy,C-reactive protein(CRP),cardiac troponin T(TnT),P-selectin(Ps),PSGL-1,cardiovascular events(cardiovascular events),and adverse events were compared.Results After treatment,the clinical efficacy in experiment group was 93.75％,which significant higher than that in control group 71.88％,the difference was statistically significant(P<0.05).The rate of cardiovascular events in experiment group was 21.88％,which significant lower than that in control group 40.63％,the difference was statistically significant(P<0.05).The serum C-reactive protein,troponin T,Ps and PSGL-1 were significantly decreased in the two groups,and the experimental group was significantly smaller than the control group,the difference was statistically significant(P<0.05).The incidence of adverse reactions was 15.63％in the control group and 9.38％in the experimental group,the difference was not statistically significant.Conclusion Danhong injection treatment of elderly patients with cardiac intervention after the clinical effect is significant,high security,the incidence of cardiovascular events is low.